Blood Res (2024) 59:8
Published online March 1, 2024
https://doi.org/10.1007/s44313-024-00011-z
© The Korean Society of Hematology
Correspondence to : *Doaa Mohamed El Demerdash
dr_eldemerdash@kasralainy.edu.eg; dr_eldemerdash@cu.edu.eg
© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background Immune thrombocytopenia (ITP) is characterized by immune response dysregulations. Cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4) plays a central role in immune checkpoint pathways and preventing autoimmune diseases by regulating immune tolerance. We aimed to explore the potential association between CTLA-4 gene polymorphisms and ITP as well as study their impact on the response to therapy.
Methods We investigated two CTLA-4 single‐nucleotide polymorphisms (SNPs; rs: 231775 and rs: 3087243) using real-time PCR as well as the plasma levels of CTLA-4 by ELISA in 88 patients with ITP and 44 healthy participants (HC).
Results CTLA-4 (rs: 3087243) A > G polymorphism analysis showed most HC had the homozygous AA genotype, which was statistically significant compared to patients with ITP. Plasma levels of CTLA4 were statistically lower in patients with acute ITP. There was no correlation between CTLA-4 (rs: 231775 and rs: 3087243) A/G SNPs were not correlated to the response to all lines of therapy assessed (corticosteroids, thrombopoietin receptor agonists, splenectomy, and rituximab).
Conclusion CTLA-4 CT 60 A/G may affect the susceptibility of ITP, but both CTLA-4 + 49 A/G and CT60 A/G did not impact the response of patients with ITP to different lines of therapy.
Keywords ITP, SNPs, Immune thrombocytopenia, Immune checkpoints, CTLA-4
Blood Res 2024; 59():
Published online March 1, 2024 https://doi.org/10.1007/s44313-024-00011-z
Copyright © The Korean Society of Hematology.
Doaa Mohamed El Demerdash1* , Maha Mohamed Saber1, Alia Ayad1, Kareeman Gomaa2 and Mohamed Abdelkader Morad1
1Internal Medicine Department, Faculty of Medicine, Teaching Kasr AL-Ainy Hospital, Cairo University, Al Kasr Al Aini, Old Cairo 4240310, Cairo Governorate, Egypt
2Clinical and Chemical Pathology Department, Faculty of Medicine, Kasr AL-Ainy Hospital, Cairo University, Cairo, Egypt
Correspondence to:*Doaa Mohamed El Demerdash
dr_eldemerdash@kasralainy.edu.eg; dr_eldemerdash@cu.edu.eg
© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background Immune thrombocytopenia (ITP) is characterized by immune response dysregulations. Cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4) plays a central role in immune checkpoint pathways and preventing autoimmune diseases by regulating immune tolerance. We aimed to explore the potential association between CTLA-4 gene polymorphisms and ITP as well as study their impact on the response to therapy.
Methods We investigated two CTLA-4 single‐nucleotide polymorphisms (SNPs; rs: 231775 and rs: 3087243) using real-time PCR as well as the plasma levels of CTLA-4 by ELISA in 88 patients with ITP and 44 healthy participants (HC).
Results CTLA-4 (rs: 3087243) A > G polymorphism analysis showed most HC had the homozygous AA genotype, which was statistically significant compared to patients with ITP. Plasma levels of CTLA4 were statistically lower in patients with acute ITP. There was no correlation between CTLA-4 (rs: 231775 and rs: 3087243) A/G SNPs were not correlated to the response to all lines of therapy assessed (corticosteroids, thrombopoietin receptor agonists, splenectomy, and rituximab).
Conclusion CTLA-4 CT 60 A/G may affect the susceptibility of ITP, but both CTLA-4 + 49 A/G and CT60 A/G did not impact the response of patients with ITP to different lines of therapy.
Keywords: ITP, SNPs, Immune thrombocytopenia, Immune checkpoints, CTLA-4
Table 1 . The clinical characteristics of patients with ITP (N, 88).
Parameter | Subcategory | Frequency | Percentage | |
---|---|---|---|---|
Sex | M | 23 | 26.1 | |
F | 65 | 73.9 | ||
Bleeding score | 0 | 7 | 7.9 | |
1 | 67 | 76.1 | ||
2 | 15 | 17 | ||
Type of bleeding | Muco-cutaneous | 79 | 89.7 | |
gastrointestinal | 7 | 8.5 | ||
Genitourinary | 38 | 43 | ||
Internal bleeding | 1 | 1.1 | ||
ITP Phase | Newly diagnosed | 4 | 4.5 | |
Persistent | 11 | 12.5 | ||
Chronic | 37 | 42 | ||
Number of lines of therapies | 1 | 4 | 4.5 | |
2 | 59 | 67 | ||
3 | 18 | 18 | ||
4 | 7 | 8 | ||
Steroid dependency | Dependent | 52 | 63.4 | |
Non-dependent | 30 | 36.6 | ||
Second line therapies | Yes | 84 | 48.7 | |
No | 4 | 51.2 | ||
Response to therapies | Corticosteroids (N, 88) | CR | 8 | 9.1 |
R | 64 | 72.7 | ||
NR | 16 | 18.2 | ||
TPO-RAs (N, 67) | CR | 18 | 26.9 | |
R | 33 | 49.3 | ||
NR | 16 | 23.9 | ||
Rituximab (N, 38) | CR | 10 | 26.3 | |
R | 16 | 42.1 | ||
NR | 12 | 31.6 | ||
Splenectomy (N, 11) | CR | 4 | 36.4 | |
R | 4 | 36.4 | ||
NR | 3 | 27.3 |
ITP Immune thrombocytopenia, N Number, TPO-RAs Thrombopoietin receptor agonists, M Male, F Female, CR Complete response, R Response, NR No response.
Table 2 . Genotypes of CTLA-4 rs231775 and rs3087243 in Patients with ITP and HC.
SNPs | Genotype | Cases (%)N, 88 | HC (%)N, 44 | P-value |
---|---|---|---|---|
rs231775 | GG | 44 (50) | 15 (34.1) | 0.206 |
GA | 35 (39.8) | 24 (54.5) | ||
AA | 9 (10.2) | 5 (11.4) | ||
rs3087243 | GG | 23 (26.1) | 9 (20.5) | 0.001* |
GA | 31 (35.2) | 0 (0) | ||
AA | 34 (38.6) | 35 (79.5) |
* Significance difference (P < 0.05); CTLA-4: cytotoxic T lymphocyte‐associated antigen‐4; ITP: immune thrombocytopenia; HC: healthy participants; SNPs: single‐nucleotide polymorphisms; N: number.
Table 3 . Correlation between Genotypes of CTLA-4 rs231775 and rs3087243 and Response to Therapies in Patients with ITP.
Line of therapy | Response | rs231775 cases (%) | P-value | rs3087243cases (%) | P-value* | ||||
---|---|---|---|---|---|---|---|---|---|
GG | GA | AA | GG | GA | AA | ||||
Corticosteroids (N, 88) | CR | 5 (11.5) | 3 (8.6) | 0 (0) | 0.948 | 2 (8.7) | 4 (12.9) | 2 (5.9) | 0.861 |
R | 32 (72.5) | 25 (71.4) | 7 (77.8) | 16 (69.6) | 22 (71) | 26 (76.5) | |||
NR | 7 (15.9) | 7 (20) | 2 (22.2) | 5 (21.7) | 5 (16.1) | 6 (17.6) | |||
TPO-RAs (N, 67) | CR | 8 (25) | 6 (22) | 4 (50) | 0.437 | 3 (18.8) | 9 (36) | 6 (23.1) | 0.676 |
R | 15 (46.9) | 16 (59.3) | 2 (25) | 8 (50) | 12 (48) | 13 (50) | |||
NR | 9 (28.7) | 5 (18.5) | 2 (25) | 5 (31.1) | 4 (16) | 7 (26.9) | |||
Rituximab (N, 38) | CR | 6 (31.6) | 3 (20) | 1 (25) | 0.926 | 2 (16.7) | 6 (54.5) | 2 (13.3) | 0.129 |
R | 8 (42.1) | 6 (40) | 2 (50) | 5 (41.7) | 2 (18.2) | 9 (60) | |||
NR | 5 (26.3) | 6 (40) | 1 (25) | 5 (41.7) | 3 (27.3) | 4 (26.7) | |||
Splenectomy (N, 11) | CR | 1 (25) | 2 (33.3) | 1 (100) | 1 | 1 (25) | 1 (50) | 2 (40) | 1 |
R | 2 (50) | 2 (33.3) | 0 (0) | 2 (50) | 1 (50) | 1 (20) | |||
NR | 1 (25) | 2 (33.3) | 0 (0) | 1 (25) | 0 (0) | 2 (40) |
CTLA-4 Cytotoxic T lymphocyte‐associated antigen‐4, ITP Immune thrombocytopenia, TPO-RAs Thrombopoietin receptor agonists, N Number, CR Complete response, R Response, NR No response; *Significance difference (P < 0.05).
Table 4 . Immune checkpoint-related gene polymorphisms in ITP.
Reference | N | Sex | Mean age (Y) | Studied polymorphisms | Conclusions |
---|---|---|---|---|---|
Wang et al., [22] | 307 | F 62%. M 38%. | 44.92 ± 14.02 | TIM3 rs10515746. CD28 rs1980422. TNFSF4 rs2205960. CTLA4 rs231779. PD1 rs36084323. ICOS rs6726035. DNAM1 rs763361. LAG3 rs870849. | CD28 rs1980422 was associated with an increased risk of ITP after false discovery rate correction (P = 0.006). The T allele of PD1 rs36084323 was a risk factor for ITP severity and the T allele of DNAM1 rs763361 for corticosteroid-resistance. The combination of TIM3 rs10515746, CD28 rs1980422, and ICOS rs6726035 best predicted a high risk of ITP. |
Chen et al., [20] | 32 | F 84.5%. M 15.5%. | 60 (median) | 12 SNPs analysis mainly focused on the promoter region of CTLA-4 and CD28 | CTLA-4 rs11571315 was a susceptible SNP for primary ITP in the Taiwan population. CTLA-4 rs5742909 was related to secondary ITP caused by autoimmune disease CTLA4 was associated with ITP but not CD28. |
Kasamatsu et al., [19] | 119 | F 73%. M 27%. | 64 (median) | DCD1 SNPs: (606 G/A, + 7209 C/T, + 63379C/T) CTLA4 SNPs: (1722 A/G, 1577 A/G, + 49 A/G, CT60 A/G) | PDCD1 + 7209 C/T SNP is associated with susceptibility to cITP. no significant differences in CTLA4 SNPs between cITP patients and healthy individuals CTLA4 1577 A/G and CT60 A/G polymorphisms may affect the severity of cITP. |
Aktürk et al., [23] | 62 | NA | NA | CTLA-4 A49G. | no association between the A49G polymorphism of the CTLA-4 gene and ITP |
Yao et al., [21] | 102 | F 70.7%. M29.3%. | 5.43 ± 3.21 (pediatric) | CTLA-4. rs11571315 and rs3087243. | CTLA4 gene is suggested to correlate with ITP through its abnormal expression level instead of gene site mutation |
Li et al., [24] | 186 | CTLA-4. 318 and CT60. | these two SNPs in CTLA-4 are not associated with susceptibility to ITP in a Chinese population | ||
Radwan et al., [25] | 100 | F 58%. M 42%. | 7.3 ± 4.4 (pediatric) | CTLA-4. exon1 49 A > G. | It did not detect a relation. between the selected CTLA-4 SNP and susceptibility to ITP in Egyptian children. |
Our presented research | 88 | F 74%. M 26%. | 32.5 (median) | CTLA-4. rs: 231,775. rs: 3,087,243. | CTLA-4 rs: 3,087,243 may affect the susceptibility of ITP. but there was no impact of both studied SNPs (rs: 231,775 and rs: 3,087,243) of CTLA-4 on the response to different lines of therapy in adult ITP patients. |
ITP Immune thrombocytopenia, CTLA-4 cytotoxic T lymphocyte‐associated antigen‐4, N number; %: percentage, Y years, M male, F female, NA None applicable; *Significance difference (P < 0.05).
Seyed Mohammad Sadegh Pezeshki, Najmadin Saki, Mehran Varnaseri Ghandali, Alireza Ekrami, Arshid Yousefi Avarvand
Blood Res 2021; 56(1): 38-43Dae Sik Kim
Blood Res 2022; 57(S1): S112-S119Young Hoon Park, Dae-Young Kim, Seongkoo Kim, Young Bae Choi, Dong-Yeop Shin, Jin Seok Kim, Won Sik Lee, Yeung-Chul Mun, Jun Ho Jang, Jong Wook Lee, Hoon Kook, on behalf of Korean Aplastic Anemia Working Party
Blood Res 2022; 57(1): 20-28